Bevacizumab, pertuzumab, and sandostatin for patients (pts) with advanced neuroendocrine cancers (NET).
Irfan Firdaus
No relevant relationships to disclose
Kent C. Shih
No relevant relationships to disclose
Ahmed Zakari
No relevant relationships to disclose
Evan Z. Lang
No relevant relationships to disclose
Michael McCleod
No relevant relationships to disclose
Kathryn B. Alguire
No relevant relationships to disclose
Nancy Walker Peacock
No relevant relationships to disclose
Douglas B. Flora
No relevant relationships to disclose
Peter Ruehlman
No relevant relationships to disclose
Chris Earwood
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose